Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAWK: Brolucizumab vs Aflibercept in nAMD
NCT02307682Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Dec 2014
- Primary completion
- Apr 2017
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Alcon Inc.. Started Dec 2014; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02307682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307682.